Table 4.
Multivariable analyses of patients with acute myeloid leukemia and complex karyotype
| Variable | Complete remission | Disease-free survival | Overall survival | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Type of complex karyotype, typical vs atypical | 0.38 (0.17-0.85) | 0.02 | 2.03 (1.03-4.01) | 0.04 | 1.86 (1.11-3.12) | 0.02 |
| Hemoglobin, continuous, per 1-unit increase | 1.27 (1.05-1.53) | 0.01 | ||||
| TP53, mutated vs wild-type | 1.75 (1.11-2.75) | 0.02 | ||||
| Age, continuous, per 10-year increase | 1.16 (1.02-1.32) | 0.02 | ||||
Abbreviations: CI, confidence interval; HR, hazard ratio; OR, odds ratio. An odds ratio <1 means a lower CR rate for the first category listed for the categorical variables. A hazard ratio >1 corresponds to a higher risk of an event for higher values of continuous variables and the first category listed of a dichotomous variable. Variables were considered for inclusion in the multivariable models if they had a univariable P-value of ≤0.20. Variables considered for inclusion in the model for achievement of CR were: the type of complex karyotype (typical vs atypical), sex (male vs female), race (white vs nonwhite), white blood cell count [(WBC) as a continuous variable, in 50-unit increments], hemoglobin (as a continuous variable, in 1-unit increments), the number of chromosome abnormalities (as a continuous variable), NPM1 mutational status (mutated vs wild-type), NRAS mutational status (mutated vs wild-type) and TP53 mutational status (mutated vs wild-type). In the model for disease-free survival, we considered the type of complex karyotype (typical vs atypical), hemoglobin (as a continuous variable, in 1-unit increments), extramedullary involvement (present vs absent), the number of chromosome abnormalities (as a continuous variable), DNMT3 mutational status (mutated vs wild-type), PHF6 mutational status (mutated vs wild-type), TET2 mutational status (mutated vs wild-type) and TP53 mutational status (mutated vs wild-type). Variables considered for inclusion in the model for overall survival were the type of complex karyotype (typical vs atypical), age (as a continuous variable, in 10-year increments), sex (male vs female), the number of chromosome abnormalities (as a continuous variable), FLT3-ITD (present vs absent), NF1 mutational status (mutated vs wild-type), PHF6 mutational status (mutated vs wild-type) and TP53 mutational status (mutated vs wild-type). See the Supplementary Information for a full list of variables evaluated in univariable analyses for all three outcome endpoints.